Last reviewed · How we verify
BSS Plus
BSS Plus is a balanced salt solution that maintains anterior chamber stability and protects corneal endothelium during intraocular surgery.
BSS Plus is a balanced salt solution that maintains anterior chamber stability and protects corneal endothelium during intraocular surgery. Used for Anterior segment intraocular surgery (corneal transplantation, cataract surgery, glaucoma surgery), Intraocular lens implantation procedures.
At a glance
| Generic name | BSS Plus |
|---|---|
| Sponsor | Adam Fedyk, MD, FACS |
| Drug class | Ophthalmic irrigating solution |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
BSS Plus is an enriched irrigating solution formulated with essential electrolytes, glucose, and glutathione to maintain the corneal endothelium and anterior chamber stability during ophthalmic procedures. It provides superior endothelial cell protection compared to standard BSS by maintaining proper osmolality, pH, and antioxidant levels throughout surgical manipulation.
Approved indications
- Anterior segment intraocular surgery (corneal transplantation, cataract surgery, glaucoma surgery)
- Intraocular lens implantation procedures
Common side effects
Key clinical trials
- Evaluating the Impact of Fat and Sugar Replacer Blends on Gastrointestinal Tolerance in Biscuits (NA)
- Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) (PHASE3)
- Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation (PHASE3)
- RESCUE and REVERSE Long-term Follow-up (PHASE3)
- Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye (PHASE2)
- Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19) (NA)
- Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis (NA)
- A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |